A Phase 2 interventional study of EGF816 and Gefitinib in Lung Cancer, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Lung Neoplasms by Massachusetts General Hospital — 17 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Massachusetts General Hospital.
Among the 49 studies in Lung Neoplasms by Massachusetts General Hospital, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2017, is one of 10 in phase 2, and was the 24th registered.
5,434 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.
Browse Lung Neoplasms studies →17 of the 49 studies in Lung Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 50–77
By country, each count listing its studies:
Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 1
First in 1993; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 60 across 3,665 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 43 interventional studies, 2,125 across the 6 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 446 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
6 of the studies in Lung Neoplasms by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06556680Massachusetts General HospitalEB-OCT Biopsy Guidance of Lung Cancer | 2026-12 |
| NCT04485286Massachusetts General HospitalEvaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury | 2027-05 |
| NCT03535545Massachusetts General HospitalPreliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | 2027-06-30 |
| NCT06910956Massachusetts General HospitalDeep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT | 2027-07-01 |
| NCT06427954Massachusetts General HospitalMobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 49 studies in Lung Neoplasms by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer.
The drugs involved in this study are:
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease or patient population. "Investigational" means that the drug or drugs are being studied and have not been approved together for patients.
The FDA (the U.S. Food and Drug Administration) has approved gefitinib as a treatment option for EGFR mutation-positive lung cancer.
The FDA has not approved EGF816 as a treatment for any disease at this time.
In this research study, the investigators are studying the safety and efficacy of the combination of the study drugs EGF816 and gefitinib.
Both EGF816 and gefitinib are inhibitors which target a specific mutation in cancer and may stop tumors growing and multiplying.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have normal organ and marrow function as defined below:
Total >1.5 x (ULN)
*For patients with Gilbert's syndrome total bilirubin >3.0 x ULN
The effects of EGF816 and gefitinib on the developing human fetus are unknown. For this reason, women of and men must agree to use highly effective during the study and for 3 months after stopping the study treatment. Highly effective contraception methods include:
Exclusion Criteria:
Patients with clinically significant, uncontrolled cardiovascular disease, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* All patients will receive gefitinib orally once daily * EGF816 will be administered orally once daily * Participant will be requested to maintain a medication diary of each dose of medication
Drug: EGF816 · Drug: Gefitinib
EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
Also known as: Iressa
9 Months Progression Free Rate
The percentage of participants that are free from objective disease progression or death at 9 months after the start treatment. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
Time frame: 9 months
Overall Response Rate (ORR)
The number of participants that achieve either a complete response (CR) or a partial response (PR). Response is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. All CRs and PRs must be confirmed by a second assessment not earlier than 4 weeks after the criteria for response are first met.
Time frame: 4 years and 4 months
Median Overall Survival
Overall survival is defined as time from the start of treatment until death or loss to follow up. Overall survival will be analyzed using the Kaplan-Meier method.
Time frame: 6 years
Median Progression Free Survival (PFS)
PFS is defined as the time from start of treatment to the time of objective disease progression, death, or loss to follow up. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
Time frame: 4.2 years
Summary of Treatment-related Adverse Events
Treatment-related adverse events, defined as those at least possibly related to study treatment, are summarized below as a measure of patient safety and treatment tolerability. Subjects were evaluated for adverse events by the Common Terminology Criteria for Adverse Events (CTCAE) v4. For each treatment-related event, subjects are counted below by the highest grade they experienced on study per CTCAE v 4.0 to demonstrate the range and severity of treatment-related toxicities documented on study. Grade refers to the severity of the toxicity, with Grade 1 corresponding to mild toxicity, Grade 2 to moderate toxicity, and Grade 3 to severe toxicity. Patients who did not experience a given event at any grade are counted in the final category for each row.
Time frame: Start of treatment through 30 days after the end of treatment (max 4 years and 5 months)
| Milestone | EGF816 + Gefitinib |
|---|---|
| Started | 11 |
| Completed | 11 |
| Not completed | 0 |
The percentage of participants that are free from objective disease progression or death at 9 months after the start treatment. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
| Participants | EGF816 + Gefitinib |
|---|---|
| 9 Months Progression Free Rate | 7 |
The number of participants that achieve either a complete response (CR) or a partial response (PR). Response is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. All CRs and PRs must be confirmed by a second assessment not earlier than 4 weeks after the criteria for response are first met.
| Participants | EGF816 + Gefitinib |
|---|---|
| Overall Response Rate (ORR) | 8 |
Overall survival is defined as time from the start of treatment until death or loss to follow up. Overall survival will be analyzed using the Kaplan-Meier method.
| months | EGF816 + Gefitinib |
|---|---|
| Median Overall Survival | 35.7 (6.18 to NA) |
PFS is defined as the time from start of treatment to the time of objective disease progression, death, or loss to follow up. Progression is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
| months | EGF816 + Gefitinib |
|---|---|
| Median Progression Free Survival (PFS) | 20.86 (5.42 to 39.57) |
Treatment-related adverse events, defined as those at least possibly related to study treatment, are summarized below as a measure of patient safety and treatment tolerability. Subjects were evaluated for adverse events by the Common Terminology Criteria for Adverse Events (CTCAE) v4. For each treatment-related event, subjects are counted below by the highest grade they experienced on study per CTCAE v 4.0 to demonstrate the range and severity of treatment-related toxicities documented on study. Grade refers to the severity of the toxicity, with Grade 1 corresponding to mild toxicity, Grade 2 to moderate toxicity, and Grade 3 to severe toxicity. Patients who did not experience a given event at any grade are counted in the final category for each row.
| Participants | EGF816 + Gefitinib |
|---|---|
| Anemia — Grade 1 (CTCAE v4) | 1 |
| Anemia — Grade 2 (CTCAE v4) | 0 |
| Anemia — Grade 3 (CTCAE v4) | 0 |
| Anemia — Subject did not experience this treatment-related toxicity | 10 |
| Cardiac disorders - other, specify — Grade 1 (CTCAE v4) | 0 |
| Cardiac disorders - other, specify — Grade 2 (CTCAE v4) | 1 |
| Cardiac disorders - other, specify — Grade 3 (CTCAE v4) | 0 |
| Cardiac disorders - other, specify — Subject did not experience this treatment-related toxicity | 10 |
| Dry eye — Grade 1 (CTCAE v4) | 1 |
| Dry eye — Grade 2 (CTCAE v4) | 0 |
| Dry eye — Grade 3 (CTCAE v4) | 0 |
| Dry eye — Subject did not experience this treatment-related toxicity | 10 |
| Eye Pain — Grade 1 (CTCAE v4) | 1 |
| Eye Pain — Grade 2 (CTCAE v4) | 0 |
| Eye Pain — Grade 3 (CTCAE v4) | 0 |
| Eye Pain — Subject did not experience this treatment-related toxicity | 10 |
| Abdominal Pain — Grade 1 (CTCAE v4) | 1 |
| Abdominal Pain — Grade 2 (CTCAE v4) | 0 |
| Abdominal Pain — Grade 3 (CTCAE v4) | 0 |
| Abdominal Pain — Subject did not experience this treatment-related toxicity | 10 |
| Bloating — Grade 1 (CTCAE v4) | 1 |
| Bloating — Grade 2 (CTCAE v4) | 0 |
| Bloating — Grade 3 (CTCAE v4) | 0 |
| Bloating — Subject did not experience this treatment-related toxicity | 10 |
| Diarrhea — Grade 1 (CTCAE v4) | 6 |
| Diarrhea — Grade 2 (CTCAE v4) | 3 |
| Diarrhea — Grade 3 (CTCAE v4) | 2 |
| Diarrhea — Subject did not experience this treatment-related toxicity | 0 |
| Dry mouth — Grade 1 (CTCAE v4) | 3 |
| Dry mouth — Grade 2 (CTCAE v4) | 0 |
| Dry mouth — Grade 3 (CTCAE v4) | 0 |
| Dry mouth — Subject did not experience this treatment-related toxicity | 8 |
| Dyspepsia — Grade 1 (CTCAE v4) | 1 |
| Dyspepsia — Grade 2 (CTCAE v4) | 0 |
| Dyspepsia — Grade 3 (CTCAE v4) | 0 |
| Dyspepsia — Subject did not experience this treatment-related toxicity | 10 |
| Gastroesophageal Reflux disease — Grade 1 (CTCAE v4) | 1 |
| Gastroesophageal Reflux disease — Grade 2 (CTCAE v4) | 0 |
| Gastroesophageal Reflux disease — Grade 3 (CTCAE v4) | 0 |
| Gastroesophageal Reflux disease — Subject did not experience this treatment-related toxicity | 10 |
| Gastrointestinal disorders - other, specify — Grade 1 (CTCAE v4) | 1 |
| Gastrointestinal disorders - other, specify — Grade 2 (CTCAE v4) | 1 |
| Gastrointestinal disorders - other, specify — Grade 3 (CTCAE v4) | 0 |
| Gastrointestinal disorders - other, specify — Subject did not experience this treatment-related toxicity | 9 |
| Mucositis oral — Grade 1 (CTCAE v4) | 1 |
| Mucositis oral — Grade 2 (CTCAE v4) | 2 |
| Mucositis oral — Grade 3 (CTCAE v4) | 0 |
| Mucositis oral — Subject did not experience this treatment-related toxicity | 8 |
| Nausea — Grade 1 (CTCAE v4) | 2 |
| Nausea — Grade 2 (CTCAE v4) | 0 |
| Nausea — Grade 3 (CTCAE v4) | 0 |
| Nausea — Subject did not experience this treatment-related toxicity | 9 |
| Oral pain — Grade 1 (CTCAE v4) | 0 |
| Oral pain — Grade 2 (CTCAE v4) | 1 |
| Oral pain — Grade 3 (CTCAE v4) | 0 |
| Oral pain — Subject did not experience this treatment-related toxicity | 10 |
| Fatigue — Grade 1 (CTCAE v4) | 3 |
| Fatigue — Grade 2 (CTCAE v4) | 0 |
| Fatigue — Grade 3 (CTCAE v4) | 0 |
| Fatigue — Subject did not experience this treatment-related toxicity | 8 |
| Fever — Grade 1 (CTCAE v4) | 0 |
| Fever — Grade 2 (CTCAE v4) | 0 |
| Fever — Grade 3 (CTCAE v4) | 1 |
| Fever — Subject did not experience this treatment-related toxicity | 10 |
| Paronychia — Grade 1 (CTCAE v4) | 2 |
| Paronychia — Grade 2 (CTCAE v4) | 2 |
| Paronychia — Grade 3 (CTCAE v4) | 0 |
| Paronychia — Subject did not experience this treatment-related toxicity | 7 |
| Alanine aminotransferase increased — Grade 1 (CTCAE v4) | 3 |
| Alanine aminotransferase increased — Grade 2 (CTCAE v4) | 2 |
| Alanine aminotransferase increased — Grade 3 (CTCAE v4) | 0 |
| Alanine aminotransferase increased — Subject did not experience this treatment-related toxicity | 6 |
| Aspartate aminotransferase increased — Grade 1 (CTCAE v4) | 4 |
| Aspartate aminotransferase increased — Grade 2 (CTCAE v4) | 0 |
| Aspartate aminotransferase increased — Grade 3 (CTCAE v4) | 0 |
| Aspartate aminotransferase increased — Subject did not experience this treatment-related toxicity | 7 |
| Electrocardiogram QT corrected interval prolonged — Grade 1 (CTCAE v4) | 1 |
| Electrocardiogram QT corrected interval prolonged — Grade 2 (CTCAE v4) | 0 |
| Electrocardiogram QT corrected interval prolonged — Grade 3 (CTCAE v4) | 0 |
| Electrocardiogram QT corrected interval prolonged — Subject did not experience this treatment-related toxicity | 10 |
| Neutrophil count decreased — Grade 1 (CTCAE v4) | 2 |
| Neutrophil count decreased — Grade 2 (CTCAE v4) | 0 |
| Neutrophil count decreased — Grade 3 (CTCAE v4) | 0 |
| Neutrophil count decreased — Subject did not experience this treatment-related toxicity | 9 |
| Weight gain — Grade 1 (CTCAE v4) | 1 |
| Weight gain — Grade 2 (CTCAE v4) | 0 |
| Weight gain — Grade 3 (CTCAE v4) | 0 |
| Weight gain — Subject did not experience this treatment-related toxicity | 10 |
| Anorexia — Grade 1 (CTCAE v4) | 1 |
| Anorexia — Grade 2 (CTCAE v4) | 0 |
| Anorexia — Grade 3 (CTCAE v4) | 0 |
| Anorexia — Subject did not experience this treatment-related toxicity | 10 |
| Hypomagnesemia — Grade 1 (CTCAE v4) | 1 |
| Hypomagnesemia — Grade 2 (CTCAE v4) | 0 |
| Hypomagnesemia — Grade 3 (CTCAE v4) | 0 |
| Hypomagnesemia — Subject did not experience this treatment-related toxicity | 10 |
| Hyponatremia — Grade 1 (CTCAE v4) | 1 |
| Hyponatremia — Grade 2 (CTCAE v4) | 0 |
| Hyponatremia — Grade 3 (CTCAE v4) | 0 |
| Hyponatremia — Subject did not experience this treatment-related toxicity | 10 |
| Metabolism and nutrition disorders - other, specify — Grade 1 (CTCAE v4) | 1 |
| Metabolism and nutrition disorders - other, specify — Grade 2 (CTCAE v4) | 0 |
| Metabolism and nutrition disorders - other, specify — Grade 3 (CTCAE v4) | 0 |
| Metabolism and nutrition disorders - other, specify — Subject did not experience this treatment-related toxicity | 10 |
| Arthralgia — Grade 1 (CTCAE v4) | 1 |
| Arthralgia — Grade 2 (CTCAE v4) | 0 |
| Arthralgia — Grade 3 (CTCAE v4) | 0 |
| Arthralgia — Subject did not experience this treatment-related toxicity | 10 |
| Myalgia — Grade 1 (CTCAE v4) | 3 |
| Myalgia — Grade 2 (CTCAE v4) | 0 |
| Myalgia — Grade 3 (CTCAE v4) | 0 |
| Myalgia — Subject did not experience this treatment-related toxicity | 8 |
| Renal and urinary disorders - other, specify — Grade 1 (CTCAE v4) | 1 |
| Renal and urinary disorders - other, specify — Grade 2 (CTCAE v4) | 0 |
| Renal and urinary disorders - other, specify — Grade 3 (CTCAE v4) | 0 |
| Renal and urinary disorders - other, specify — Subject did not experience this treatment-related toxicity | 10 |
| Erectile dysfunction — Grade 1 (CTCAE v4) | 1 |
| Erectile dysfunction — Grade 2 (CTCAE v4) | 0 |
| Erectile dysfunction — Grade 3 (CTCAE v4) | 0 |
| Erectile dysfunction — Subject did not experience this treatment-related toxicity | 10 |
| Vaginal pain — Grade 1 (CTCAE v4) | 1 |
| Vaginal pain — Grade 2 (CTCAE v4) | 0 |
| Vaginal pain — Grade 3 (CTCAE v4) | 0 |
| Vaginal pain — Subject did not experience this treatment-related toxicity | 10 |
| Cough — Grade 1 (CTCAE v4) | 0 |
| Cough — Grade 2 (CTCAE v4) | 1 |
| Cough — Grade 3 (CTCAE v4) | 0 |
| Cough — Subject did not experience this treatment-related toxicity | 10 |
| Dyspnea — Grade 1 (CTCAE v4) | 0 |
| Dyspnea — Grade 2 (CTCAE v4) | 1 |
| Dyspnea — Grade 3 (CTCAE v4) | 0 |
| Dyspnea — Subject did not experience this treatment-related toxicity | 10 |
| Epistaxis — Grade 1 (CTCAE v4) | 1 |
| Epistaxis — Grade 2 (CTCAE v4) | 0 |
| Epistaxis — Grade 3 (CTCAE v4) | 0 |
| Epistaxis — Subject did not experience this treatment-related toxicity | 10 |
| Pneumonitis — Grade 1 (CTCAE v4) | 0 |
| Pneumonitis — Grade 2 (CTCAE v4) | 1 |
| Pneumonitis — Grade 3 (CTCAE v4) | 0 |
| Pneumonitis — Subject did not experience this treatment-related toxicity | 10 |
| Sore throat — Grade 1 (CTCAE v4) | 0 |
| Sore throat — Grade 2 (CTCAE v4) | 1 |
| Sore throat — Grade 3 (CTCAE v4) | 0 |
| Sore throat — Subject did not experience this treatment-related toxicity | 10 |
| Alopecia — Grade 1 (CTCAE v4) | 1 |
| Alopecia — Grade 2 (CTCAE v4) | 1 |
| Alopecia — Grade 3 (CTCAE v4) | 0 |
| Alopecia — Subject did not experience this treatment-related toxicity | 9 |
| Bullous dermatitis — Grade 1 (CTCAE v4) | 0 |
| Bullous dermatitis — Grade 2 (CTCAE v4) | 1 |
| Bullous dermatitis — Grade 3 (CTCAE v4) | 0 |
| Bullous dermatitis — Subject did not experience this treatment-related toxicity | 10 |
| Dry skin — Grade 1 (CTCAE v4) | 4 |
| Dry skin — Grade 2 (CTCAE v4) | 1 |
| Dry skin — Grade 3 (CTCAE v4) | 0 |
| Dry skin — Subject did not experience this treatment-related toxicity | 6 |
| Erythema multiforme — Grade 1 (CTCAE v4) | 2 |
| Erythema multiforme — Grade 2 (CTCAE v4) | 0 |
| Erythema multiforme — Grade 3 (CTCAE v4) | 0 |
| Erythema multiforme — Subject did not experience this treatment-related toxicity | 9 |
| Pain of skin — Grade 1 (CTCAE v4) | 1 |
| Pain of skin — Grade 2 (CTCAE v4) | 1 |
| Pain of skin — Grade 3 (CTCAE v4) | 0 |
| Pain of skin — Subject did not experience this treatment-related toxicity | 9 |
| Pruritis — Grade 1 (CTCAE v4) | 4 |
| Pruritis — Grade 2 (CTCAE v4) | 1 |
| Pruritis — Grade 3 (CTCAE v4) | 0 |
| Pruritis — Subject did not experience this treatment-related toxicity | 6 |
| Rash acneiform — Grade 1 (CTCAE v4) | 5 |
| Rash acneiform — Grade 2 (CTCAE v4) | 2 |
| Rash acneiform — Grade 3 (CTCAE v4) | 0 |
| Rash acneiform — Subject did not experience this treatment-related toxicity | 4 |
| Rash maculo-papular — Grade 1 (CTCAE v4) | 3 |
| Rash maculo-papular — Grade 2 (CTCAE v4) | 2 |
| Rash maculo-papular — Grade 3 (CTCAE v4) | 3 |
| Rash maculo-papular — Subject did not experience this treatment-related toxicity | 3 |
| Scalp pain — Grade 1 (CTCAE v4) | 1 |
| Scalp pain — Grade 2 (CTCAE v4) | 0 |
| Scalp pain — Grade 3 (CTCAE v4) | 0 |
| Scalp pain — Subject did not experience this treatment-related toxicity | 10 |
| Skin/subcutaneous tissue disorders - other, specify — Grade 1 (CTCAE v4) | 3 |
| Skin/subcutaneous tissue disorders - other, specify — Grade 2 (CTCAE v4) | 1 |
| Skin/subcutaneous tissue disorders - other, specify — Grade 3 (CTCAE v4) | 0 |
| Skin/subcutaneous tissue disorders - other, specify — Subject did not experience this treatment-related toxicity | 7 |
Collected over Adverse events are collected from informed consent until 30 days after the end of treatment (maximum 4 years and 5 months). Patients were monitored for survival up to 6 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EGF816 + Gefitinib | 4/11 (36.4%) | 2/11 (18.2%) | 11/11 (100%) |
| Event | EGF816 + Gefitinib |
|---|---|
| FeverGeneral disorders | 1/11 |
| Pericardial effusionCardiac disorders | 1/11 |
| Event | EGF816 + Gefitinib |
|---|---|
| DiarrheaGastrointestinal disorders | 11/11 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 8/11 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 7/11 |
| Rash acneiformSkin and subcutaneous tissue disorders | 7/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/11 |
| FatigueGeneral disorders | 6/11 |
| Alanine aminotransferase increasedInvestigations | 5/11 |
| Dry skinSkin and subcutaneous tissue disorders | 5/11 |
| FeverGeneral disorders | 5/11 |
| HypertensionVascular disorders | 5/11 |
| Age, Continuous(years) | EGF816 + Gefitinib |
|---|---|
| Median | 58 (47 to 72) |
| Sex: Female, Male(Participants) | EGF816 + Gefitinib |
|---|---|
| Female | 5 |
| Male | 6 |
| Race (NIH/OMB)(Participants) | EGF816 + Gefitinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2021, 50 months.
Results were first posted in Jun 2025, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nazartinib
Massachusetts General Hospital →